A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2

Cancer Research

Volumn 59, Issue 6, 1999, Pages 1268-1272

  Rohlff, Christian ^a,d   Watson, Susan A ^b   Morris, Teresa M ^b   Skelton, Lorraine ^c   Jackman, Ann L ^c   Page, Martin J ^a  

^a Abingdon Science Park   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c CRC Centre for Cancer Therapeutics   (United Kingdom)

^d Oxford GlycoSciences   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; NUCLEOSIDE ANALOG; OGT 719; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLORECTAL TUMOR; DRUG EFFICACY; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ASIALOGLYCOPROTEIN RECEPTOR; CELL MEMBRANE; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; RECEPTORS, CELL SURFACE; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0033559540     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics. CA Cancer J Clin., 48: 6-29, 1998.
2. Finlay, I. G., and McArdle, C. S. Effect of occult hepatic metastasis on survival after curative resection for colorectal carcinoma. Gastroenterology, 85: 596-599, 1983.
3. Russell, A. H., Tong, D., Dawson, L. K., and Wisbeck, W. Adenocarcinoma of the proximal colon. Sites of initial dissemination and patterns of recurrence following, surgery alone. Cancer (Phila.), 53: 360-367, 1984.
4. Bertino, J. R. Biomodulation of 5-fluorouracil with antifolates. Semin. Oncol., 24: S18-52-S18-56, 1997.
5. Grem, J. L. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin. Semin. Oncol., 24: S18-8-S18-18, 1997.
6. Machover, D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer (Phila.), 80: 1179-1187, 1997.
7. Zaniboni, A. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. J. Clin. Oncol., 15: 2432-2441, 1997.
8. Pritchard, D. M., Watson, A. J., Potten, C. S., Jackman, A. L., and Hickman, J. A. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc. Natl. Acad. Sci. USA. 94: 1795-1799, 1997.
9. Ardalan, B., and Glazer, R. An update on the biochemistry of 5-fluorouracil. Cancer Treat. Rev., 8: 157-167, 1981.
10. Budman, D. R., Meropol, N. J., Reigner, B., Creaven, P. J., Lichtman, S. M., Berghorn, E., Behr, J., Gordon, R. J., Osterwalder, B., and Griffin, T. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine, J. Clin. Oncol., 16: 1795-1802, 1998.
11. Pazdur, R., Lassere, Y., Diaz-Canton, E., and Ho, D. H. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule. Cancer Invest., 16: 145-151, 1998.
12. Kojima, T., Suzumura, K., Kanemitsu, T., Miyashita, A., Inamura, Y., Owa, Y., and Naruse, T. Concentrations of 5-fluorouracil (5-FU) in serum and tissues after venous injection of legafur or 5-FU-clinical study on colorectal cancer. Gan. To Kagaku Ryoho., 25: 547-551, 1998.
13. Trinh, Q. T., Austin, E. A., Murray, D. M. Knick, V. C., and Huber, B. E. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res., 55: 4808-4812, 1995.
14. Weiss, P., and Ashwell, G. The asialoglycoprotein receptor: properties and modulation by ligand. Prog. Clin. Biol. Res., 300: 169-184, 1989.
15. Lodish, H. F. Recognition of complex oligosaccharides by the multi-subunit asialoglycoprotein receptor. Trends Biochem. Sci., 16: 374-377, 1991.
16. Lee, R. T. Ligand structural requirements for recognition and binding by the hepatic asialoglycoprotein receptor. Targeted Diagn. Ther., 4: 65-86, 1991.
17. Pacifico, F., Laviola, L., Ulianich, L., Porcellini, A., Ventra, C., Consiglio, E., and Avvedimento, V. E. Differential expression of the asialoglycoprotein receptor in discrete brain areas, in kidney and thyroid. Biochem. Biophys. Res. Commun., 210: 138-144, 1995.
18. Ashwell, G., and Morell, A. G. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv. Enzymol. Areas Mol. Biol., 41: 99-128, 1974.
19. Abdullah, M., and Kierszenbaum, A. L. Identification of rat testis galactosyl receptor using antibodies to liver asialoglycoprotein receptor: purification and localization on surfaces of spermatogenic cells and sperm. J. Cell Biol., 108: 367-375, 1989.
20. Huber, B. E. Late-stage spermatids are characterized by expression of the "liver-specific" asialoglycoprotein receptor, RHL-1. Mol. Pharmacol., 41: 639-644, 1992.
21. Kempka, G., Roos, P. H., and Kolb-Bachofen, V. A membrane-associated form of C-reactive protein is the galactose-specific particle receptor on rat liver macrophages. J. Immunol., 144: 1004-1009, 1990.
22. Roos, P. H., Hartman, H. J., Schlepper-Schafer, J., Kolb, H., and Kolb-Bachofen, V. Galactose-specific receptors on liver cells. II. Characterization of the purified receptor from macrophages reveals no structural relationship to the hepatocyte receptor. Biochim. Biophys. Acta, 847: 115-121, 1985.
23. Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T., and Sato, J. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res., 42: 3858-3862, 1982.
24. Schwartz, A. L., Fridovich, S. E., Knowles, B. B., and Lodish, H. F. Characterization of the asialoglycoprotein receptor in a continuous hepatoma line. J. Biol. Chem., 256: 8878-8881, 1981.
25. Park, J. H., Cho, E. W., Shin, S. Y., Lee, Y. J., and Kim, K. L. Detection of the asialoglycoprotein receptor on cell lines of extrahepatic origin. Biochem. Biophys. Res. Commun., 244, 304-311, 1998.
26. Mu, J. Z., Gordon, M., Shao, J. S., and Alpers, D. H. Apical expression of functional asialoglycoprotein receptor in the human intestinal cell line HT-29. Gastroenterology, 113: 1501-1509, 1997.
27. Watson, S. A., Morris, T. M., Crossbee, D. M., and Hardcastle, J. D. A new hepatic invasive human colorectal xenograft model. Eur. J. Cancer, 29: 1740-1745, 1993.
28. Watson, S. A., Morris, T. M., Robinson, G., Crimmin, M. J., Brown, P. D., and Hardcastle, J. D. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res., 55: 3629-3633, 1995.
29. Watson, S. A., Morris, T. M., Parsons, S. L., Steele, R. J., and Brown, P. D. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human coloreclal cancer ascites model. Br. J. Cancer. 74: 1354-1358, 1996.
30. Jackinan, A. L., and Calvert, A. U. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann. Oncol., 6: 871-881, 1995.
31. Twentyman, P. R., and Luscombe, M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br. J. Cancer. 56: 279-285, 1987.
32. 10-propargyl-5.8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies. Cancer Res., 46: 2810-2815, 1986.
33. 10-propargyl-5,8-didea7afolic acid (ICI 198583). Biochem. Pharmacol., 42: 1885-1895, 1991.
34. Yalowich, J. C., and Kalman, T. I. Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro. Biochem. Pharmacol., 34: 2319-2324, 1985.
35. Taylor, G. A., Jackman, A. L., Balmanno, K., Hughes, L. R., and Calvert, A. H. Estimation of the in vitro and in vivo inhibitory effects of antifolates upon thymidylate synthase (TS) in whole cells. Adv. Exp. Med. Biol., 253B: 383-388, 1989.
36. El Sayed, Y. M., Naguib, F. M. N., Park, K. S., Cha, S., Darnowski, J. W., and Soong, S. J. The fluoropyrimidines. In: M. M. Mes, G. Powis, and J. S. Kovach (eds.), Pharmacokinetics of Anticancer Agents in Humans, pp. 209-227. Amsterdam: Elsevier, 1990.
37. Myers, C. E. The pharmacology of fluoropyrimidines. Pharmacol. Rev., 33: 1-15, 1981.
38. Bider, M. D., Wahlberg, J. M., Kammerer, R. A., and Spiess, M. The oligomerization domain of the asialoglycoprotein receptor preferentially forms 2:2 heterotetramers in vitro. J. Biol. Chem., 271: 31996-32001, 1996.
39. Bider, M. D., Cescalo, R., Jeno, P., and Spies, M. High-affinity ligand binding to subunit H1 of the asialoglycoprolein receptor in the absence of subunit H2. Eur. J. Biochem., 230: 201-213, 1995.
40. Spiess, M., and Lodish, H. F. Sequence of a second human asialoglycoprotein receptor: conservation of two receptor genes during evolution. Proc. Natl. Acad. Sci. USA, 82: 6465-6469, 1985.
41. Vaughn, D. J., and Treat, J. Cancers of the large bowel and hepatobiliary tract. In: H. M. Pinedo, D. L. Longo, and B. A. Chabner (eds.), Cancer Chemotherapy Biologic Response Modifiers, Vol. 15, pp. 508-520. New York: Elsevier Science. 1994.
42. Fink, U., Molle, B., Dascher, H., Ermisch, S., Loffel, J., and Herman, R. Phase II study of gemcitabine in metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 15: 507, 1992.
43. Uchida, M., Kamiya, K., Yoshimura, T., Sasaki, K., Tsutani, H., Nakamura, T., and Ho, D. H. Activities of enzymes convening 5-fluorouracil to 5-fluorouridine-5′-monophosphate and 5-fluorodeoxyuridine-5′-monophosphate in subcultured cell lines and solid tumor tissues. Nippon Gan. Chiryo Gakkai Shi, 25: 990-996, 1990.
44. Uchida, M., Brown, N., and Ho, D. H. Enzymatic conversion of 5-fluoro-2′-deoxyuridine to 5-fluorouracil or 5-fluoro-2′-deoxyuridine 5′-monophosphate in human tissues. Anticancer Res., 10: 779-783, 1990.
45. Geoffroy, F. J., Allegra, C. J., Sinha, B., and Grem, J. L. Enhances cytotoxicity with interleukin-1α and 5-fluorouracil in HCT116 colon cancer cells. Oncol. Res., 6: 581-591, 1994.